We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

AMIC® Chondro-Gide®

AMIC® Chondro-Gide® is a minimally-invasive 1-step procedure that can be performed either by mini-open surgery, or in an arthroscopic manner. Developed by Geistlich Surgery in collaboration with leading surgeons in Europe, this technique has been effective in repairing chondral or osteochondral defects in the knee, talus,  and hip.1,2,3 

The Benefits of Using AMIC® Chondro-Gide®

With both mini-open and arthroscopic techniques, the unique advantage of AMIC® Chondro-Gide® is that it supports the body’s own potential to heal itself. Damaged cartilage is removed, and then bone marrow stimulation (BMS) techniques are used to bring regeneration supporting cells to the defect site.

The membrane covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces on the delicate superclot. At the same time, it functions as the roof of a biological chamber that forms over the defect.  The biocompatible collagen material provides an environment for cell growth4 and is replaced by new cartilage tissue over time.5

 

Developed to Support Regeneration: AMIC® Chondro-Gide® 

 

References

  1. VOLZ, M., et al. A randomized controlled trial demonstrating sustained benefit of Autologous Matrix-Induced Chondrogenesis over microfracture at five years. Int Orthop, Apr 2017, 41(4), 797-804) (Clinical study)
  2. JANELLI, E, et al. Arthroscopic treatment of chondral defects (Clinical study); in the hip: AMIC®, MACI, microfragmented adipose tissue transplantation (MATT) and other options. SICOT J, 2017, 3(43). www.sicot-org/articles/sicotj/abs/2017/01/sicotj170008/sicotj170008.html (Clinical study) 
  3. Geistlich Pharma AG data on file (Bench test) 
  4. GILLE, J., et al. Cell-Laden and Cell-Free Matrix-Induced-Chondrogenesis versus Microfracture for the Treatment of Articular Cartilage Defects: A Histological and Biomechanical Study in Sheep. Cartilage OnlineFirst, January 7, 2010, doi:10.1177/1947603509358721 (Pre-clinical study)
  5. STEADMAN, J.R., Microfracture Technique for Full-Thickness Chondral Defects: Technique and Clinical Results. Operative Techniques in Orthopaedics. 1997. 7(4), 300-304. (Clinical study)

 

Dr. Sanja Saftic
International Product Manager